GPR55 and ovarian neoplasm: Although beyond the scope of this study, it would be of interest to study the effect of the pharmacological GPR55 inhibitor CID16020046 on ovarian tumour size and vascularity in mice, and furthermore to investigate the involvement of ovarian tumour angiogenesis in GPR55 knockout mice in vivo.